Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients.

NCT06231745 is registered in ClinicalTrials.gov with Mostafa Bahaa as lead sponsor.

NCT NCT06231745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06231745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients.
Lead sponsor
Mostafa Bahaa
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2024
Completion date
July 20, 2025
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis